191 related articles for article (PubMed ID: 28512306)
1. Structure Based docking studies towards exploring potential anti-androgen activity of selected phytochemicals against Prostate Cancer.
Singh AN; Baruah MM; Sharma N
Sci Rep; 2017 May; 7(1):1955. PubMed ID: 28512306
[TBL] [Abstract][Full Text] [Related]
2. Endocrine Disruption at the Androgen Receptor: Employing Molecular Dynamics and Docking for Improved Virtual Screening and Toxicity Prediction.
Wahl J; Smieško M
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29914135
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of MEL-3, a novel AR antagonist that suppresses prostate cancer cell growth.
Helsen C; Marchand A; Chaltin P; Munck S; Voet A; Verstuyf A; Claessens F
Mol Cancer Ther; 2012 Jun; 11(6):1257-68. PubMed ID: 22496481
[TBL] [Abstract][Full Text] [Related]
4. Modeling androgen receptor flexibility: a binding mode hypothesis of CYP17 inhibitors/antiandrogens for prostate cancer therapy.
Gianti E; Zauhar RJ
J Chem Inf Model; 2012 Oct; 52(10):2670-83. PubMed ID: 22924551
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis and Evaluation of Novel Substituted (5-methyl-1H-pyrazol-3-yl)- 1,3,4-oxadiazole as Potent Androgen Receptor Antagonist.
Andavar S; Vaithilingam M; Selvaraj D; Kumaran AA; Devanathan K
Anticancer Agents Med Chem; 2020; 20(1):84-93. PubMed ID: 31755396
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety.
Chen H; Zhang J; Hu P; Qian Y; Li J; Shen J
Bioorg Med Chem; 2019 Oct; 27(20):115081. PubMed ID: 31493989
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
8. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
[TBL] [Abstract][Full Text] [Related]
9. Molecular Docking of Phytochemicals Targeting GFRs as Therapeutic Sites for Cancer: an In Silico Study.
Mendie LE; Hemalatha S
Appl Biochem Biotechnol; 2022 Jan; 194(1):215-231. PubMed ID: 34988844
[TBL] [Abstract][Full Text] [Related]
10. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
Liu H; An X; Li S; Wang Y; Li J; Liu H
Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer.
Purawarga Matada GS; Dhiwar PS; Abbas N; Singh E; Ghara A; Das A; Bhargava SV
J Biomol Struct Dyn; 2022 Aug; 40(13):6183-6192. PubMed ID: 33525984
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic studies, molecular docking, and molecular dynamics simulations of phytochemicals from Morus alba: a multi receptor approach for potential therapeutic agents in colorectal cancer.
Stany B; Mishra S; Rao KVB
Med Oncol; 2024 May; 41(6):156. PubMed ID: 38750377
[TBL] [Abstract][Full Text] [Related]
15. Structure-based virtual screening and identification of a novel androgen receptor antagonist.
Song CH; Yang SH; Park E; Cho SH; Gong EY; Khadka DB; Cho WJ; Lee K
J Biol Chem; 2012 Aug; 287(36):30769-80. PubMed ID: 22798067
[TBL] [Abstract][Full Text] [Related]
16. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.
Lallous N; Leblanc E; Munuganti RS; Hassona MD; Nakouzi NA; Awrey S; Morin H; Roshan-Moniri M; Singh K; Lawn S; Yamazaki T; Adomat HH; Andre C; Daugaard M; Young RN; Guns ES; Rennie PS; Cherkasov A
Mol Cancer Ther; 2016 Dec; 15(12):2936-2945. PubMed ID: 27765852
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel Androgen Receptor Ligands by Structure-based Virtual Screening and Bioassays.
Zhou W; Duan M; Fu W; Pang J; Tang Q; Sun H; Xu L; Chang S; Li D; Hou T
Genomics Proteomics Bioinformatics; 2018 Dec; 16(6):416-427. PubMed ID: 30639122
[TBL] [Abstract][Full Text] [Related]
18. Combining empirical knowledge, in silico molecular docking and ADMET profiling to identify therapeutic phytochemicals from Brucea antidysentrica for acute myeloid leukemia.
Bultum LE; Tolossa GB; Lee D
PLoS One; 2022; 17(7):e0270050. PubMed ID: 35895695
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel antagonists targeting the DNA binding domain of androgen receptor by integrated docking-based virtual screening and bioassays.
Pang JP; Shen C; Zhou WF; Wang YX; Shan LH; Chai X; Shao Y; Hu XP; Zhu F; Zhu DY; Xiao L; Xu L; Xu XH; Li D; Hou TJ
Acta Pharmacol Sin; 2022 Jan; 43(1):229-239. PubMed ID: 33767381
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents.
Chen H; Yu YZ; Tian XM; Wang CL; Qian YN; Deng ZA; Zhang JX; Lv DJ; Zhang HB; Shen JL; Yuan M; Zhao SC
Bioorg Med Chem; 2019 Jan; 27(1):133-143. PubMed ID: 30482547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
